CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
ACT01 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02126670
NCT02126670Phase 2Completed
CompareCT.gov

ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis

Promius Pharma, LLC·interventional·Posted Apr 30, 2014·Updated Feb 22, 2016

In Brief

A Phase 2 clinical trial evaluating ACT01, Comp01, and 3 other interventions for Actinic Keratosis. Completed, enrolled 100 participants across 4 sites.

Detailed Summary

The purpose of this study is to determine whether or not ACT01 is effective and tolerable alone or when used in combination with Comp01, Comp02, Comp03 or Comp04 in patients with facial and/or scalp keratosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActinic Keratosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 30, 2014
Enrollment StartApr 1, 2014
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 12.2 years ago

Interventions

ACT01drug

Comp01drug

Comp02drug

Comp03drug

Comp04drug